Alright I will give you apes the solution to the question what business will be one of the biggest AI benefactors, and why you Bagholders should sell Adobe to buy ...
RELX plc, formerly Reed Elsevier
ticker on LSE: REL
essentially the leading player in the Analytics Industry, RELX owns established, trusted, and patented data collections and databases, ranging from insurance claims, over medical research, to legal precedent cases and case studies
being led by the same innocent looking swede, [Erik Engström](https://en.wikipedia.org/wiki/Erik_Engstr%C3%B6m) , since 2007, who has turned this company from a legacy bookprinting and publishing operation to the data aggregator that the entire insurance, law, medicine and scientific research sectors worldwide rely on. there is simply no other company of equal scale, this deeply embedded in its customers operations.
If you were to look at a graph of their return on invested capital its actually laughably how straight up and to the right moves from 16% 7 years ago to 23% today, achieved by an increase in turnover, growth, AND margin. Its one thing to pull this off for 1 year, or a 2-3 years streak but my guy Erik has been at it relentlessly for almost 20 years now, and he doesnt seem to think about stopping, with relx overshooting their targeted long term growth rate of 4-5 % for multiple years in a row now. Even the latest revenues were a big surprise with RELX growth actually accelerating despite the cooked up claude fears. Yet the price didnt budge, thats where you know u should get greedy because you are dealing with a fearful selling-side.
Their only real competitors Thomson Reuters and Wolters Kluwer operate a level of analytics which are way less valuable, easier to compete in and easier to disrupt since they rely primarily on information readily available at-source, whereas RELX IS the source for most of its data (like ID and Drivers License Scans, or Insurance Claims Registry which are mandatory)
Whoever of you has ever read a scientific paper will recognize the name Elsevier
Actually I feel kind of dumb for telling you guys, because at current prices below 30€ per share this company is such an obvious steal it's laughable. Company is buying back shares like crazy, from 2022 cf for buybacks of 500m turning to 1.500m cash for buybacks, at the most opportune prices
Like tell me why/where im wrong, I dont see ANYBODY mention this company anywhere, not even the "value investing" substack blogs. I cant be the only sane person in the room able to read their financial statements
but until then, I will wait for the next round of dividends to buy RELX stock cya